Across TCGA pan-cancer cohorts, KRTAP5-5 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of KRTAP5-5’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where KRTAP5-5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KRTAP5-5 is over-expressed in tumor, although a few such as HNSC and KIRC show the opposite, repressed pattern.

LIHC, STAD, and HNSC are the cancer types where KRTAP5-5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRTAP5-5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.247	.002	4	view →
STAD	All	All	+0.278	.005	3	view →
HNSC	Female	III,IV	−0.178	.046	2	view →
KIRC	All	III,IV	−0.037	.016	2	view →
LUSC	All	All	+0.081	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: KRTAP5-5 RNA expression & survival · all KRTAP5-5 data types